Directorio
We are doing this study to find the most effective, safe dose of an experimental drug called epcoritamab (the study drug). We want to know how well this study drug works in people with relapsed/refractory CLL and Richter's Syndrome.
If you and your family join this study, you will:<ul>
<li>Have a 2-3 hour visit in the clinic to meet with the study doctor</li>
<li>Have blood drawn for a test called Exome sequencing</li>
<li>Have a telephone discussion of test results when they are available (6-9 months after the blood is drawn)</li>
<li>Have a 1 hour discussion of test results in the clinic after the telephone discussion</li></ul>
We are doing this study to find out if giving heated chemotherapy into the belly, a procedure known as heated intraperitoneal chemotherapy (HIPEC), can improve treatment results for patients with ovarian cancer.
We are doing this study to find out if an experimental drug combination of mirvetuximab (MIRV) plus bevacizumab (BEV) is more effective at managing platinum-sensitive ovarian and fallopian tube cancers in a maintenance setting than bevacizumab on its own.
We are doing this study to find out if a drug called selinexor (the study drug) is a safe and effective option for maintenance therapy for patients with TP53 wild-type endometrial cancer who had a positive response to treatment with chemotherapy.
We are doing this study to find out if an investigational drug called RO7446603 (the study drug) is a safe treatment for diabetic macular edema. We will give the drug at different doses and also want to understand the way the body processes the drug.
We are doing this study to compare different approaches to pain relief for people with sickle cell disease (SCD). We want to find if acupuncture or guided relaxation therapies are helpful methods to lower pain from SCD, and we also want to find out which options work best for most people.
We are doing this study is to find out if an investigational drug called imetelstat (the study drug) can lead to better outcomes in people who have myelofibrosis (MF) when it is compared to other available therapies.